ALFASIGMA SPA
- Country
- 🇮🇹Italy
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.alfasigma.com
Clinical Trials
43
Trial Phases
3 Phases
Drug Approvals
36
Drug Approvals
Levocarnitine Oral Solution
- Product Name
- 左卡尼汀口服溶液
- Approval Number
- 国药准字HJ20171307
- Approval Date
- Jan 26, 2025
Levocarnitine Oral Solution
- Product Name
- 左卡尼汀口服溶液
- Approval Number
- 国药准字HJ20171308
- Approval Date
- Jan 26, 2025
Low Molecular Weight Heparin Sodium Injection
- Product Name
- 希弗全
- Approval Number
- 国药准字HJ20140282
- Approval Date
- Mar 15, 2021
Low Molecular Weight Heparin Sodium Injection
- Product Name
- 希弗全
- Approval Number
- 国药准字HJ20140280
- Approval Date
- Mar 15, 2021
Low Molecular Weight Heparin Sodium Injection
- Product Name
- 希弗全
- Approval Number
- 国药准字HJ20140281
- Approval Date
- Mar 15, 2021
Levocarnitine Oral Solution
- Product Name
- 左卡尼汀口服溶液
- Approval Number
- H20171308
- Approval Date
- Jun 24, 2019
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (40 trials with phase data)• Click on a phase to view related trials
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 80
- Registration Number
- NCT06865417
- Locations
- 🇧🇪
Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola, Brussels, Belgium
🇧🇪Centre Hospitalier Regional De La Citadelle, Liege, Belgium
🇧🇪Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Namur, Belgium
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 10
- Registration Number
- NCT06222034
- Locations
- 🇫🇷
CHU Amiens - Hopital Nord, Amiens Cedex 1, France
🇫🇷Bicêtre University Hospital, Le Kremlin Bicêtre, France
🇩🇪Children's university hospital Charité, Campus Virchow, SPZ, Berlin, Germany
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 520
- Registration Number
- NCT05817942
- Locations
- 🇦🇹
LKH - Universitätsklinikum Graz, Graz, Austria
🇦🇹Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
🇦🇹KH der Barmherzigen Brüder St.Veit an der Glan, Sankt Veit an der Glan, Austria
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
- Conditions
- Axial Spondyloarthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 495
- Registration Number
- NCT05785611
- Locations
- 🇧🇪
Cliniques Universitaires de Bruxelles Hopital Erasme, Brussels, Belgium
🇧🇪ReumaClinic, Genk, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
- Conditions
- Chronic Intestinal Pseudo-obstruction
- Interventions
- Drug: Velusetrag 15 mg once daily for 4 weeks.Drug: Placebo once daily for 4 weeks.
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 17
- Registration Number
- NCT05724069
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg Campus, Leuven, Belgium
🇮🇹Policlinico S.Orsola-Malpighi, Bologna, Italy
🇮🇹Aou Arcispedale Sant'Anna Di Cona, Cona, Italy
- Prev
- 1
- 2
- 3
- 4
- Next
News
Intercept Pharmaceuticals Voluntarily Withdraws OCALIVA from US Market Following FDA Request
Intercept Pharmaceuticals announced the voluntary withdrawal of OCALIVA (obeticholic acid) from the US market for primary biliary cholangitis treatment following an FDA request.
Obeticholic Acid Shows Long-Term Benefit in Primary Biliary Cholangitis
COBALT trial data, published in *The American Journal of Gastroenterology*, shows obeticholic acid (OCA) significantly reduces adverse outcomes in PBC patients.